

# Daniel J Sargent

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3680970/publications.pdf>

Version: 2024-02-01

356  
papers

48,810  
citations

3874

91  
h-index

1919

214  
g-index

365  
all docs

365  
docs citations

365  
times ranked

36057  
citing authors

#	ARTICLE	IF	CITATIONS
1	Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials. <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100492.	0.5	5
2	Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. <i>JCO Precision Oncology</i> , 2020, 4, 116-127.	1.5	4
3	An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles. <i>Journal of Biopharmaceutical Statistics</i> , 2019, 29, 271-286.	0.4	10
4	Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer. <i>Annals of Surgery</i> , 2019, 269, 589-595.	2.1	283
5	Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. <i>Journal of the National Cancer Institute</i> , 2018, 110, 638-648.	3.0	90
6	Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. <i>European Journal of Cancer</i> , 2018, 96, 115-124.	1.3	2
7	Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 696-703.	1.1	11
8	Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1177-1188.	13.9	699
9	A hierarchical Bayesian design for randomized Phase II clinical trials with multiple groups. <i>Journal of Biopharmaceutical Statistics</i> , 2018, 28, 451-462.	0.4	4
10	Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 379.	3.4	104
11	Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). <i>Journal of Geriatric Oncology</i> , 2018, 9, 24-31.	0.5	10
12	Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. <i>European Journal of Cancer</i> , 2018, 103, 205-213.	1.3	13
13	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. <i>Lancet, The</i> , 2018, 391, 2128-2139.	6.3	1,487
14	Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance). <i>International Journal of Statistics in Medical Research</i> , 2018, 7, 137-146.	0.5	0
15	A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles. <i>Statistics in Medicine</i> , 2017, 36, 67-80.	0.8	14
16	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017, 35, 1453-1486.	0.8	255
17	Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 552-560.	0.8	87
18	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 625-657.	1.2	75

#	ARTICLE	IF	CITATIONS
19	Molecular Biomarkers for the Evaluation of Colorectal Cancer. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 187-225.	1.2	108
20	Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. <i>Oncologist</i> , 2017, 22, 189-198.	1.9	9
21	Use of Bayesian Decision Analysis to Minimize Harm in Patient-Centered Randomized Clinical Trials in Oncology. <i>JAMA Oncology</i> , 2017, 3, e170123.	3.4	25
22	Molecular Biomarkers for the Evaluation of Colorectal Cancer. <i>American Journal of Clinical Pathology</i> , 2017, 147, 221-260.	0.4	32
23	Association of DNA Mismatch Repair and Mutations in <i>BRAF</i> and <i>KRAS</i> With Survival After Recurrence in Stage III Colon Cancers. <i>JAMA Oncology</i> , 2017, 3, 472.	3.4	82
24	Prognostic Value of <i>BRAF</i> and <i>KRAS</i> Mutations in MSI and MSS Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw272.	3.0	201
25	Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis. <i>Lancet Oncology</i> , The, 2017, 18, 143-154.	5.1	68
26	The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project. <i>Oncologist</i> , 2017, 22, 1415-1418.	1.9	7
27	Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data. <i>Clinical Trials</i> , 2017, 14, 611-620.	0.7	7
28	Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, 124-128.	1.0	37
29	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline Summary From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. <i>Journal of Oncology Practice</i> , 2017, 13, 333-337.	2.5	29
30	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. <i>Journal of Clinical Oncology</i> , 2017, 35, 1929-1937.	0.8	37
31	Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance). <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 1-11.	0.6	7
32	Title is missing!. , 2017, , .		56
33	Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3579-3579.	0.8	9
34	Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX +/- cetuximab chemotherapy: NCCTG N0147 (Alliance).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3516-3516.	0.8	2
35	Statistics and Clinical Trials. , 2016, , 239-252.e1.		0
36	Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147. <i>International Journal of Cancer</i> , 2016, 139, 986-995.	2.3	16

#	ARTICLE	IF	CITATIONS
37	Surrogate End Points in Soft Tissue Sarcoma: Methodologic Challenges. <i>Journal of Clinical Oncology</i> , 2016, 34, 3949-3950.	0.8	3
38	Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. <i>Journal of Geriatric Oncology</i> , 2016, 7, 422-429.	0.5	9
39	Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the Power of Pooled Individual Patient Data from Multiple Clinical Trials. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 251-259.	1.0	0
40	American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 370-374.	157.7	280
41	Further Evaluating the Benefit of Adjuvant Chemotherapy for Colon Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3711-3712.	0.8	6
42	Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw154.	3.0	18
43	Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). <i>Oncologist</i> , 2016, 21, 1509-1521.	1.9	33
44	Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 133-137.	0.7	28
45	Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. <i>Lancet Oncology</i> , The, 2016, 17, 1709-1719.	5.1	442
46	Flexible Bayesian Survival Modeling with Semiparametric Time-Dependent and Shape-Restricted Covariate Effects. <i>Bayesian Analysis</i> , 2016, 11, 381-402.	1.6	16
47	Testing of evaluation bias for progression free survival endpoint in oncology clinical trials. <i>Statistics in Medicine</i> , 2016, 35, 3923-3932.	0.8	0
48	Adjuvant Therapy for Colon Cancer. <i>JAMA Oncology</i> , 2016, 2, 1133.	3.4	8
49	New insights into the evaluation of randomized controlled trials for rare diseases over a long-term research horizon: a simulation study. <i>Statistics in Medicine</i> , 2016, 35, 3245-3258.	0.8	8
50	Clinical trial designs incorporating predictive biomarkers. <i>Cancer Treatment Reviews</i> , 2016, 43, 74-82.	3.4	61
51	One good DNA-damage deserves another: Oxaliplatin in MSI-high colon cancer. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw011.	3.0	9
52	Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. <i>Journal of Clinical Oncology</i> , 2016, 34, 1182-1189.	0.8	32
53	Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. <i>Journal of Clinical Oncology</i> , 2016, 34, 843-853.	0.8	128
54	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. <i>Journal of Clinical Oncology</i> , 2016, 34, 144-150.	0.8	116

#	ARTICLE	IF	CITATIONS
55	Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study. <i>Blood</i> , 2016, 128, 1102-1102.	0.6	3
56	Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients. <i>Blood</i> , 2016, 128, 3027-3027.	0.6	5
57	Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients. <i>Blood</i> , 2016, 128, 4196-4196.	0.6	1
58	Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the power of pooled individual patient data from multiple clinical trials. <i>Chinese Clinical Oncology</i> , 2016, 5, 80-80.	0.4	6
59	The Direct Assignment Option as a Modular Design Component: An Example for the Setting of Two Predefined Subgroups. <i>Computational and Mathematical Methods in Medicine</i> , 2015, 2015, 1-6.	0.7	2
60	Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv239.	3.0	18
61	Resampling the N9741 Trial to Compare Tumor Dynamic Versus Conventional End Points in Randomized Phase II Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 36-41.	0.8	15
62	Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 1036-1043.	3.2	31
63	Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv186.	3.0	98
64	Improved Outcomes in Metastatic Colon Cancer. <i>JAMA Oncology</i> , 2015, 1, 795.	3.4	4
65	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. <i>Lancet Oncology</i> , The, 2015, 16, 937-948.	5.1	286
66	Prognostic Value of Molecular Detection of Lymph Node Metastases After Curative Resection of Stage II Colon Cancer: A Systematic Pooled Data Analysis. <i>Clinical Colorectal Cancer</i> , 2015, 14, 99-105.	1.0	3
67	Impact of Copula Directional Specification on Multi-Trial Evaluation of Surrogate End Points. <i>Journal of Biopharmaceutical Statistics</i> , 2015, 25, 857-877.	0.4	9
68	Genotype-based clinical trials in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2015, 12, 475-487.	6.1	37
69	Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods. <i>Journal of Clinical Oncology</i> , 2015, 33, 4048-4057.	0.8	6
70	Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). <i>Clinical Cancer Research</i> , 2015, 21, 5294-5304.	3.2	70
71	Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1346.	3.8	898
72	The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv157.	3.0	28

#	ARTICLE	IF	CITATIONS
73	Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups. <i>Lung Cancer</i> , 2015, 90, 281-287.	0.9	6
74	New Adjuvant Trial Designs in Colon Cancer. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 326-334.	1.0	2
75	Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes. <i>Gastroenterology</i> , 2015, 148, 88-99.	0.6	273
76	Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. <i>Journal of Clinical Oncology</i> , 2015, 33, 22-28.	0.8	87
77	Comparing and Validating Simple Measures of Patient- Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. <i>SOJ Anesthesiology &amp; Pain Management</i> , 2015, 2, .	0.1	9
78	Introduction to special issue on biomarker-based clinical trial designs in oncology. <i>Chinese Clinical Oncology</i> , 2015, 4, 28.	0.4	0
79	Randomized Phase II Clinical Trials. <i>Journal of Biopharmaceutical Statistics</i> , 2014, 24, 802-816.	0.4	11
80	Association Study of the let-7 miRNA-Complementary Site Variant in the 3' UTR of the KRAS Gene in Stage III Colon Cancer (NCCTG N0147 Clinical Trial). <i>Clinical Cancer Research</i> , 2014, 20, 3319-3327.	3.2	40
81	DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG T3247). <i>Journal of Clinical Oncology</i> , 2014, 32, 2975-2982.	3.0	136
82	Association of Age With Survival in Patients With Metastatic Colorectal Cancer: Analysis From the ARCAD Clinical Trials Program. <i>Journal of Clinical Oncology</i> , 2014, 32, 2975-2982.	0.8	118
83	Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. <i>Clinical Cancer Research</i> , 2014, 20, 4210-4217.	3.2	56
84	Molecular Testing for Lymph Node Metastases as a Determinant of Colon Cancer Recurrence: Results from a Retrospective Multicenter Study. <i>Clinical Cancer Research</i> , 2014, 20, 4361-4369.	3.2	18
85	ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	62
86	The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: Results of a survey in the oncology community. <i>European Journal of Cancer</i> , 2014, 50, 260-266.	1.3	34
87	Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147. <i>Clinical Colorectal Cancer</i> , 2014, 13, 100-109.	1.0	41
88	KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance). <i>Clinical Cancer Research</i> , 2014, 20, 3033-3043.	3.2	129
89	Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 1031-1039.	0.8	216
90	Shifting paradigms in cancer clinical trial design. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 625-626.	12.5	8

#	ARTICLE	IF	CITATIONS
91	Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	140
92	American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes. <i>Journal of Clinical Oncology</i> , 2014, 32, 1277-1280.	0.8	354
93	Evaluation of Alternate Categorical Tumor Metrics and Cut Points for Response Categorization Using the RECIST 1.1 Data Warehouse. <i>Journal of Clinical Oncology</i> , 2014, 32, 841-850.	0.8	40
94	Center-within-trial versus trial-level evaluation of surrogate endpoints. <i>Computational Statistics and Data Analysis</i> , 2014, 78, 1-20.	0.7	10
95	Calibration of Quality-Adjusted Life Years for Oncology Clinical Trials. <i>Journal of Pain and Symptom Management</i> , 2014, 47, 1091-1099.e3.	0.6	6
96	Exploring the statistical and clinical impact of two interim analyses on the Phase II design with option for direct assignment. <i>Contemporary Clinical Trials</i> , 2014, 38, 157-162.	0.8	2
97	Projecting Event-Based Analysis Dates in Clinical Trials: An Illustration Based on the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration. <i>Projecting Analysis Dates for the IDEA Collaboration. Forum of Clinical Oncology</i> , 2014, 5, 1-7.	0.1	2
98	Biomarker-driven Studies in Metastatic Colorectal Cancer (mCRC): Challenges and Opportunities. <i>The Journal of Oncopathology</i> , 2014, 2, 37-45.	0.1	0
99	Germline Variation in Colorectal Risk Loci Does Not Influence Treatment Effect or Survival in Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2014, 9, e94727.	1.1	4
100	Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine. <i>Chinese Clinical Oncology</i> , 2014, 3, 14.	0.4	9
101	Adaptive randomized phase II design for biomarker threshold selection and independent evaluation. <i>Chinese Clinical Oncology</i> , 2014, 3, .	0.4	5
102	Drug rechallenge and treatment beyond progression—implications for drug resistance. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 571-587.	12.5	219
103	Statistical issues in the validation of prognostic, predictive, and surrogate biomarkers. <i>Clinical Trials</i> , 2013, 10, 647-652.	0.7	26
104	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2013, 381, 303-312.	6.3	2,276
105	Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 3664-3672.	0.8	233
106	Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1667-1670.	3.0	78
107	Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis. <i>European Journal of Cancer</i> , 2013, 49, 1565-1577.	1.3	136
108	The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 261-269.	1.0	94

#	ARTICLE	IF	CITATIONS
109	Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. <i>Cancer</i> , 2013, 119, 1528-1536.	2.0	141
110	Current Use and Surgical Efficacy of Laparoscopic Colectomy in Colon Cancer. <i>Journal of the American College of Surgeons</i> , 2013, 217, 56-62.	0.2	13
111	Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1600-1607.	3.0	133
112	A phase II flexible screening design allowing for interim analysis and comparison with historical control. <i>Contemporary Clinical Trials</i> , 2013, 35, 128-137.	0.8	2
113	A review of phase II trial designs for initial marker validation. <i>Contemporary Clinical Trials</i> , 2013, 36, 597-604.	0.8	27
114	The Predictive and Prognostic Value of Sex in Early-Stage Colon Cancer: A Pooled Analysis of 33,345 Patients from the ACCENT Database. <i>Clinical Colorectal Cancer</i> , 2013, 12, 179-187.	1.0	27
115	Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database. <i>Journal of Clinical Oncology</i> , 2013, 31, 2600-2606.	0.8	211
116	Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database. <i>Journal of Clinical Oncology</i> , 2013, 31, 3656-3663.	0.8	65
117	Adaptive adjustment of the randomization ratio using historical control data. <i>Clinical Trials</i> , 2013, 10, 430-440.	0.7	86
118	Associations Between Cigarette Smoking Status and Colon Cancer Prognosis Among Participants in North Central Cancer Treatment Group Phase III Trial N0147. <i>Journal of Clinical Oncology</i> , 2013, 31, 2016-2023.	0.8	49
119	Application of Tumor Measurement-Based Metrics in the Real World. <i>Journal of Clinical Oncology</i> , 2013, 31, 4374-4374.	0.8	4
120	Disease-Free Survival in Colon Cancer: Still Relevant After All These Years!. <i>Journal of Clinical Oncology</i> , 2013, 31, 1609-1610.	0.8	12
121	Surgical Quality Surrogates Do Not Predict Colon Cancer Survival in the Setting of Technical Credentialing. <i>Annals of Surgery</i> , 2013, 257, 102-107.	2.1	25
122	Mining the ACCENT database: a review and update. <i>Chinese Clinical Oncology</i> , 2013, 2, 18.	0.4	7
123	Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1383.	3.8	412
124	Comparative Effectiveness of Oxaliplatin vs Non-Oxaliplatin-containing Adjuvant Chemotherapy for Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2012, 104, 211-227.	3.0	90
125	Benefits and Adverse Events in Younger Versus Older Patients Receiving Adjuvant Chemotherapy for Colon Cancer: Findings From the Adjuvant Colon Cancer Endpoints Data Set. <i>Journal of Clinical Oncology</i> , 2012, 30, 2334-2339.	0.8	34
126	Reply to S.A. Kesikli et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 2288-2289.	0.8	1



#	ARTICLE	IF	CITATIONS
127	From isolated hypotheses to connected practical studies: statisticians's role in a seamless targeted therapy development. <i>Future Medicinal Chemistry</i> , 2012, 4, 943-945.	1.1	1
128	A 2-Stage Phase II Design with Direct Assignment Option in Stage II for Initial Marker Validation. <i>Clinical Cancer Research</i> , 2012, 18, 4225-4233.	3.2	17
129	Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841. <i>Journal of Clinical Oncology</i> , 2012, 30, 263-267.	0.8	483
130	Association of Obesity With DNA Mismatch Repair Status and Clinical Outcome in Patients With Stage II or III Colon Carcinoma Participating in NCCTG and NSABP Adjuvant Chemotherapy Trials. <i>Journal of Clinical Oncology</i> , 2012, 30, 406-412.	0.8	51
131	Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups. <i>Clinical Cancer Research</i> , 2012, 18, 256-262.	3.2	61
132	The ARCAD Clinical Trials Program: An Update and Invitation. <i>Oncologist</i> , 2012, 17, 188-191.	1.9	9
133	Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models. <i>Bayesian Analysis</i> , 2012, 7, 639-674.	1.6	132
134	CRM Trials for Assessing Toxicity and Efficacy. , 2012, , 85-96.		1
135	Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. <i>Lancet Oncology</i> , The, 2012, 13, e196-e204.	5.1	49
136	Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 356-362.	0.6	15
137	Molecular Pathways: Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive, and Therapeutic Implications. <i>Clinical Cancer Research</i> , 2012, 18, 1506-1512.	3.2	217
138	Meta-analysis for Surrogacy: Accelerated Failure Time Models and Semicompeting Risks Modeling. <i>Biometrics</i> , 2012, 68, 226-232.	0.8	15
139	Rejoinder for "Meta-analysis for Surrogacy: Accelerated Failure Time Models and Semicompeting Risks Modeling". <i>Biometrics</i> , 2012, 68, 245-247.	0.8	2
140	Predicting Treatment Effect from Surrogate Endpoints and Historical Trials: An Extrapolation Involving Probabilities of a Binary Outcome or Survival to a Specific Time. <i>Biometrics</i> , 2012, 68, 248-257.	0.8	14
141	Bayesian Adaptive Trial Design for a Newly Validated Surrogate Endpoint. <i>Biometrics</i> , 2012, 68, 258-267.	0.8	8
142	Prognostic Impact of FoxP3+ Regulatory T Cells in Relation to CD8+ T Lymphocyte Density in Human Colon Carcinomas. <i>PLoS ONE</i> , 2012, 7, e42274.	1.1	84
143	Bayesian adjusted $R^2$ for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials. <i>Statistics in Medicine</i> , 2012, 31, 743-761.	0.8	26
144	On Bayesian methods of exploring qualitative interactions for targeted treatment. <i>Statistics in Medicine</i> , 2012, 31, 3693-3707.	0.8	14

#	ARTICLE	IF	CITATIONS
145	Taking the long view: how to design a series of Phase III trials to maximize cumulative therapeutic benefit. <i>Clinical Trials</i> , 2012, 9, 283-292.	0.7	19
146	Exploring racial differences in outcome and treatment for metastatic colorectal cancer. <i>Cancer</i> , 2012, 118, 1083-1090.	2.0	34
147	A phase II trial design with direct assignment option for initial marker validation.. <i>Journal of Clinical Oncology</i> , 2012, 30, 34-34.	0.8	1
148	<i>Statistics and Clinical Trials.</i> , 2012, , 223-237.		0
149	A comprehensive analysis of clinical and tumor characteristics with BRAF and KRAS mutations status in adjuvant colon cancer trial N0147.. <i>Journal of Clinical Oncology</i> , 2012, 30, 446-446.	0.8	0
150	Use of FoxP3+ and cytotoxic CD8+ T lymphocytes to identify a patient subgroup with a favorable prognosis similar to colon cancers with deficient DNA mismatch (dMMR) repair.. <i>Journal of Clinical Oncology</i> , 2012, 30, 460-460.	0.8	0
151	Evaluation of the prognostic value of guanylyl cyclase C (GCC) lymph node (LN) classification in patients with stage II colon cancer: A pooled analysis.. <i>Journal of Clinical Oncology</i> , 2012, 30, 443-443.	0.8	0
152	Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials. <i>Journal of Clinical Oncology</i> , 2011, 29, 2781-2786.	0.8	61
153	Integrating biomarkers in clinical trials. <i>Expert Review of Molecular Diagnostics</i> , 2011, 11, 171-182.	1.5	124
154	Failure of bevacizumab in early-stage colon cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 10-11.	12.5	4
155	DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2011, 103, 863-875.	3.0	469
156	Optimism bias leads to inconclusive resultsâ€”an empirical study. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 583-593.	2.4	45
157	All-Comers versus Enrichment Design Strategy in Phase II Trials. <i>Journal of Thoracic Oncology</i> , 2011, 6, 658-660.	0.5	21
158	Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials. <i>Biometrics</i> , 2011, 67, 1047-1056.	0.8	250
159	Statistical Considerations for the Next Generation of Clinical Trials. <i>Seminars in Oncology</i> , 2011, 38, 598-604.	0.8	10
160	Long-Term Follow-Up and Individual Item Analysis of Quality of Life Assessments Related to Laparoscopic-Assisted Colectomy in the COST Trial 93-46-53 (INT 0146). <i>Annals of Surgical Oncology</i> , 2011, 18, 2422-2431.	0.7	68
161	Evaluation of Guanylyl Cyclase C Lymph Node Status for Colon Cancer Staging and Prognosis. <i>Annals of Surgical Oncology</i> , 2011, 18, 3261-3270.	0.7	30
162	Incorporation of Biomarker Assessment in Novel Clinical Trial Designs: Personalizing Brain Tumor Treatments. <i>Current Oncology Reports</i> , 2011, 13, 42-49.	1.8	21

#	ARTICLE	IF	CITATIONS
163	Prognostic web-based models for stage II and III colon cancer. <i>Cancer</i> , 2011, 117, 4155-4165.	2.0	25
164	Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials. <i>Computational Statistics and Data Analysis</i> , 2011, 55, 2748-2757.	0.7	23
165	Design of clinical trials for biomarker research in oncology. <i>Clinical Investigation</i> , 2011, 1, 1627-1636.	0.0	21
166	Alternative End Points to Evaluate a Therapeutic Strategy in Advanced Colorectal Cancer: Evaluation of Progression-Free Survival, Duration of Disease Control, and Time to Failure of Strategy—An Aide et Recherche en Cancérologie Digestive Group Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4199-4204.	0.8	51
167	Comparison of Continuous versus Categorical Tumor Measurement-Based Metrics to Predict Overall Survival in Cancer Treatment Trials. <i>Clinical Cancer Research</i> , 2011, 17, 6592-6599.	3.2	27
168	Tumor Status at 12 Weeks Predicts Survival in Advanced Colorectal Cancer: Findings from NCCTG N9741. <i>Oncologist</i> , 2011, 16, 859-867.	1.9	16
169	Outcomes Among Black Patients With Stage II and III Colon Cancer Receiving Chemotherapy: An Analysis of ACCENT Adjuvant Trials. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1498-1506.	3.0	61
170	Time to Initiation of Adjuvant Chemotherapy and Survival in Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1199.	3.8	10
171	Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue. <i>Journal of Clinical Oncology</i> , 2011, 29, 4620-4626.	0.8	178
172	Systemic Therapy for Elderly Patients with Gastrointestinal Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2011, 5, CMO.S6983.	0.6	2
173	Using cure models and multiple imputation to utilize recurrence as an auxiliary variable for overall survival. <i>Clinical Trials</i> , 2011, 8, 581-590.	0.7	7
174	Survival Is Not a Good Outcome for Randomized Trials With Effective Subsequent Therapies. <i>Journal of Clinical Oncology</i> , 2011, 29, 4719-4720.	0.8	33
175	Vitamin D Status in Patients With Stage IV Colorectal Cancer: Findings From Intergroup Trial N9741. <i>Journal of Clinical Oncology</i> , 2011, 29, 1599-1606.	0.8	85
176	Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. <i>Clinical Trials</i> , 2011, 8, 591-600.	0.7	20
177	Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials. <i>Biostatistics</i> , 2011, 12, 478-492.	0.9	31
178	Phase III Clinical Trials with Anticancer Agents. , 2011, , 163-188.		0
179	Randomized Phase II Trials: Time for a New Era in Clinical Trial Design. <i>Journal of Thoracic Oncology</i> , 2010, 5, 932-934.	0.5	53
180	Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: A pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials. <i>International Journal of Oncology</i> , 2010, 36, 601-6.	1.4	43

#	ARTICLE	IF	CITATIONS
181	Adjuvant Therapy for Colon Cancer: Learning from the Past to Inform the Future. <i>Annals of Surgical Oncology</i> , 2010, 17, 947-949.	0.7	5
182	Predictive biomarker validation in practice: lessons from real trials. <i>Clinical Trials</i> , 2010, 7, 567-573.	0.7	83
183	Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741. <i>Journal of Clinical Oncology</i> , 2010, 28, 3227-3233.	0.8	198
184	Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients. <i>Cancer</i> , 2010, 116, 1691-1698.	2.0	20
185	Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: Methods and challenges. <i>Statistics in Medicine</i> , 2010, 29, 1077-1083.	0.8	55
186	Comparison of Error Rates in Single-Arm Versus Randomized Phase II Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , 2010, 28, 1936-1941.	0.8	96
187	Clinical Trials Data Collection: When Less Is More. <i>Journal of Clinical Oncology</i> , 2010, 28, 5019-5021.	0.8	11
188	Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. <i>Clinical Trials</i> , 2010, 7, 312-321.	0.7	87
189	Obesity Is an Independent Prognostic Variable in Colon Cancer Survivors. <i>Clinical Cancer Research</i> , 2010, 16, 1884-1893.	3.2	191
190	Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1729.	3.8	711
191	Reply to D.J. Stewart. <i>Journal of Clinical Oncology</i> , 2010, 28, e652-e653.	0.8	3
192	Reply to M.A. Rosen et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e161-e161.	0.8	1
193	Toward Efficient Trials in Colorectal Cancer: The ARCAD Clinical Trials Program. <i>Journal of Clinical Oncology</i> , 2010, 28, 527-530.	0.8	23
194	Comparison of histopathology and RT-qPCR amplification of guanylyl cyclase C for detection of colon cancer metastases in lymph nodes. <i>Journal of Clinical Pathology</i> , 2010, 63, 530-537.	1.0	31
195	Reply to C.D. Atkins. <i>Journal of Clinical Oncology</i> , 2010, 28, e747-e747.	0.8	0
196	Reply to P. Prassopoulos et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e82-e82.	0.8	0
197	Blinded Independent Central Review of the Progression-Free Survival Endpoint. <i>Oncologist</i> , 2010, 15, 492-495.	1.9	37
198	Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set. <i>Journal of Clinical Oncology</i> , 2010, 28, 460-465.	0.8	67

#	ARTICLE	IF	CITATIONS
199	Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3219-3226.	0.8	1,352
200	Revised Tumor and Node Categorization for Rectal Cancer Based on Surveillance, Epidemiology, and End Results and Rectal Pooled Analysis Outcomes. <i>Journal of Clinical Oncology</i> , 2010, 28, 256-263.	0.8	204
201	Evaluation of the Value of Attribution in the Interpretation of Adverse Event Data: A North Central Cancer Treatment Group and American College of Surgeons Oncology Group Investigation. <i>Journal of Clinical Oncology</i> , 2010, 28, 3002-3007.	0.8	42
202	Reply to I.D. Nagtegaal et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e399-e400.	0.8	0
203	The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. <i>Clinical Cancer Research</i> , 2010, 16, 1764-1769.	3.2	143
204	Causal Effects of Treatments for Informative Missing Data due to Progression/Death. <i>Journal of the American Statistical Association</i> , 2010, 105, 912-929.	1.8	9
205	Designing a Randomized Clinical Trial to Evaluate Personalized Medicine: A New Approach Based on Risk Prediction. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1756-1759.	3.0	14
206	What Constitutes Reasonable Evidence of Efficacy and Effectiveness to Guide Oncology Treatment Decisions?. <i>Oncologist</i> , 2010, 15, 19-23.	1.9	31
207	Biomarkers and surrogate end points—the challenge of statistical validation. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 309-317.	12.5	283
208	Revised TN Categorization for Colon Cancer Based on National Survival Outcomes Data. <i>Journal of Clinical Oncology</i> , 2010, 28, 264-271.	0.8	481
209	Randomized Phase II Trials: Inevitable or Inadvisable?. <i>Journal of Clinical Oncology</i> , 2010, 28, 2641-2647.	0.8	78
210	Clinical Validation of Biomarkers in Cancer. , 2010, , 227-250.		0
211	Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics. <i>Transactions of the American Clinical and Climatological Association</i> , 2010, 121, 21-32; discussion 32-3.	0.9	2
212	CAUSAL EFFECTS OF TREATMENTS FOR INFORMATIVE MISSING DATA DUE TO PROGRESSION/DEATH. <i>Journal of the American Statistical Association</i> , 2010, 105, 912-929.	1.8	6
213	Functional and Clinical Significance of Variants Localized to 8q24 in Colon Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2492-2500.	1.1	37
214	Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 1948-1955.	0.8	160
215	Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 3677-3683.	0.8	1,166
216	Early Stopping for Benefit in National Cancer Institute–Sponsored Randomized Phase III Trials: The System Is Working. <i>Journal of Clinical Oncology</i> , 2009, 27, 1543-1544.	0.8	8

#	ARTICLE	IF	CITATIONS
217	Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials. <i>Journal of Clinical Oncology</i> , 2009, 27, 872-877.	0.8	539
218	Phase III Noninferiority Trial Comparing Irinotecan With Oxaliplatin, Fluorouracil, and Leucovorin in Patients With Advanced Colorectal Carcinoma Previously Treated With Fluorouracil: N9841. <i>Journal of Clinical Oncology</i> , 2009, 27, 2848-2854.	0.8	59
219	Role of Sensitivity Analyses in Assessing Progression-Free Survival in Late-Stage Oncology Trials. <i>Journal of Clinical Oncology</i> , 2009, 27, 5958-5964.	0.8	36
220	Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147. <i>Oncology</i> , 2009, 77, 120-123.	0.9	67
221	Current Issues in Oncology Drug Development, with a Focus on Phase II Trials. <i>Journal of Biopharmaceutical Statistics</i> , 2009, 19, 556-562.	0.4	19
222	Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All. <i>Journal of Biopharmaceutical Statistics</i> , 2009, 19, 530-542.	0.4	106
223	Evaluation of the Optimal Number of Lesions Needed for Tumor Evaluation Using the Response Evaluation Criteria in Solid Tumors: A North Central Cancer Treatment Group Investigation. <i>Journal of Clinical Oncology</i> , 2009, 27, 3205-3210.	0.8	34
224	NCCTG Study N9741: Leveraging Learning from an NCI Cooperative Group Phase III Trial. <i>Oncologist</i> , 2009, 14, 970-978.	1.9	11
225	Racial Differences in Advanced Colorectal Cancer Outcomes and Pharmacogenetics: A Subgroup Analysis of a Large Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 4109-4115.	0.8	74
226	Postoperative Surveillance Recommendations for Early Stage Colon Cancer Based on Results From the Clinical Outcomes of Surgical Therapy Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 3671-3676.	0.8	91
227	Reply to F. Montagnani et al. <i>Journal of Clinical Oncology</i> , 2009, 27, e134-e135.	0.8	0
228	Alternate Endpoints for Screening Phase II Studies. <i>Clinical Cancer Research</i> , 2009, 15, 1873-1882.	3.2	78
229	Cost implications of new treatments for advanced colorectal cancer. <i>Cancer</i> , 2009, 115, 2081-2091.	2.0	54
230	Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. <i>International Journal of Clinical Oncology</i> , 2009, 14, 102-111.	1.0	70
231	Evolving end points for clinical trials in advanced colorectal cancer. <i>Current Colorectal Cancer Reports</i> , 2009, 5, 135-139.	1.0	1
232	Bayesian Variable Selection with Joint Modeling of Categorical and Survival Outcomes: An Application to Individualizing Chemotherapy Treatment in Advanced Colorectal Cancer. <i>Biometrics</i> , 2009, 65, 1030-1040.	0.8	14
233	Optimising the design of phase II oncology trials: The importance of randomisation. <i>European Journal of Cancer</i> , 2009, 45, 275-280.	1.3	119
234	Intraepithelial Effector (CD3+)/Regulatory (FoxP3+) T-Cell Ratio Predicts a Clinical Outcome of Human Colon Carcinoma. <i>Gastroenterology</i> , 2009, 137, 1270-1279.	0.6	273

#	ARTICLE	IF	CITATIONS
235	Long-Term Survivors of Metastatic Colorectal Cancer Treated with Systemic Chemotherapy Alone: A North Central Cancer Treatment Group Review of 3811 Patients, N0144. <i>Clinical Colorectal Cancer</i> , 2009, 8, 88-93.	1.0	64
236	Genomic advances and their impact on clinical trial design. <i>Genome Medicine</i> , 2009, 1, 69.	3.6	16
237	Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges. <i>Journal of Clinical Oncology</i> , 2009, 27, 4027-4034.	0.8	364
238	Clinical implications of microsatellite instability in sporadic colon cancers. <i>Current Opinion in Oncology</i> , 2009, 21, 369-373.	1.1	80
239	Reply to M. Chao et al. <i>Journal of Clinical Oncology</i> , 2009, 27, e281-e281.	0.8	1
240	Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144. <i>Clinical Colorectal Cancer</i> , 2009, 8, 88-93.	1.0	2
241	Importance of randomization in early clinical trials. <i>Clinical Advances in Hematology and Oncology</i> , 2009, 7, 249-51.	0.3	0
242	Individual data pooled analyses to improve understanding of adjuvant therapy in colon cancer: Review of the ACCENT collaborative group. <i>Current Colorectal Cancer Reports</i> , 2008, 4, 155-159.	1.0	1
243	A false discovery rate based loss framework for selection of interactions. <i>Statistics in Medicine</i> , 2008, 27, 2004-2021.	0.8	3
244	Systematic review of statistical methods used in molecular marker studies in cancer. <i>Cancer</i> , 2008, 112, 1862-1868.	2.0	35
245	North Central Cancer Treatment Group's Achievements and Perspectives. <i>Seminars in Oncology</i> , 2008, 35, 530-544.	0.8	6
246	Clinical Trials of Novel and Targeted Therapies: Endpoints, Trial Design, and Analysis. <i>Cancer Investigation</i> , 2008, 26, 439-444.	0.6	14
247	Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE). <i>Journal of Clinical Oncology</i> , 2008, 26, 5326-5334.	0.8	654
248	Prognostic Significance of Defective Mismatch Repair and BRAF V600E in Patients with Colon Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 3408-3415.	3.2	218
249	Prognostic Impact of Bim, Puma, and Noxa Expression in Human Colon Carcinomas. <i>Clinical Cancer Research</i> , 2008, 14, 5810-5818.	3.2	74
250	Surrogate endpoint validation: statistical elegance versus clinical relevance. <i>Statistical Methods in Medical Research</i> , 2008, 17, 477-486.	0.7	26
251	Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107. <i>Journal of Clinical Oncology</i> , 2008, 26, 183-189.	0.8	169
252	Assessing the Measure of a New Drug: Is Survival the Only Thing That Matters?. <i>Journal of Clinical Oncology</i> , 2008, 26, 1922-1923.	0.8	70

#	ARTICLE	IF	CITATIONS
253	Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741. <i>Journal of Clinical Oncology</i> , 2008, 26, 5721-5727.	0.8	274
254	New Lessons From "Old" Chemotherapy in Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4532-4534.	0.8	5
255	Proapoptotic Bad and Bid Protein Expression Predict Survival in Stages II and III Colon Cancers. <i>Clinical Cancer Research</i> , 2008, 14, 4128-4133.	3.2	41
256	Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741. <i>Clinical Cancer Research</i> , 2008, 14, 8263-8269.	3.2	52
257	Survival Following Recurrence in Stage II and III Colon Cancer: Findings From the ACCENT Data Set. <i>Journal of Clinical Oncology</i> , 2008, 26, 2336-2341.	0.8	193
258	Surgeon Volume Does Not Predict Outcomes in the Setting of Technical Credentialing. <i>Annals of Surgery</i> , 2008, 248, 746-750.	2.1	63
259	Genomic classifiers in colon cancer - clinical utility. <i>Gastrointestinal Cancer Research: GCR</i> , 2008, 2, S35-7.	0.8	1
260	Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5218-5224.	0.8	321
261	Adjuvant Therapy in the Elderly: Making the Right Decision. <i>Journal of Clinical Oncology</i> , 2007, 25, 1870-1875.	0.8	75
262	Smoothing Balanced Single-Error-Term Analysis of Variance. <i>Technometrics</i> , 2007, 49, 12-25.	1.3	25
263	Priorities in Colorectal Cancer Research: Recommendations From the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. <i>Journal of Clinical Oncology</i> , 2007, 25, 2313-2321.	0.8	25
264	Impact of Complete Response to Chemotherapy on Overall Survival in Advanced Colorectal Cancer: Results From Intergroup N9741. <i>Journal of Clinical Oncology</i> , 2007, 25, 3469-3474.	0.8	68
265	End Points for Colon Cancer Adjuvant Trials: Observations and Recommendations Based on Individual Patient Data From 20,898 Patients Enrolled Onto 18 Randomized Trials From the ACCENT Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 4569-4574.	0.8	220
266	End Points in Advanced Colon Cancer Clinical Trials: A Review and Proposal. <i>Journal of Clinical Oncology</i> , 2007, 25, 3572-3575.	0.8	66
267	Sound Footing or Slippery Slope? The Value of Secondary Analyses of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2007, 25, 3191-3193.	0.8	2
268	Laparoscopically Assisted vs Open Colectomy for Colon Cancer. <i>Archives of Surgery</i> , 2007, 142, 298.	2.3	485
269	Laparoscopic Colectomy for Cancer Is Not Inferior to Open Surgery Based on 5-Year Data From the COST Study Group Trial. <i>Annals of Surgery</i> , 2007, 246, 655-664.	2.1	962
270	Adverse-event rates: journals versus databases. <i>Lancet</i> , The, 2007, 369, 171-172.	6.3	3



#	ARTICLE	IF	CITATIONS
271	Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?. Lancet, The, 2007, 370, 105-107.	6.3	33
272	CAIRO and FOCUS – Authors' reply. Lancet, The, 2007, 370, 1905.	6.3	2
273	FDG-PET Lymphoma Demonstration Project Invitational Workshop. Academic Radiology, 2007, 14, 330-339.	1.3	27
274	Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability. International Journal of Cancer, 2007, 120, 1232-1238.	2.3	32
275	Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX). Cancer, 2007, 110, 670-677.	2.0	29
276	Prediction of Radial Distance of Extraprostatic Extension From Pretherapy Factors. International Journal of Radiation Oncology Biology Physics, 2007, 69, 411-418.	0.4	18
277	Method for evaluating prediction models that apply the results of randomized trials to individual patients. Trials, 2007, 8, 14.	0.7	81
278	An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations. Statistics in Medicine, 2007, 26, 2317-2330.	0.8	72
279	Randomized Controlled Trial of Reduced-Dose Bolus Fluorouracil Plus Leucovorin and Irinotecan or Infused Fluorouracil Plus Leucovorin and Oxaliplatin in Patients With Previously Untreated Metastatic Colorectal Cancer: A North American Intergroup Trial. Journal of Clinical Oncology, 2006, 24, 3347-3353.	0.8	205
280	Prognostic Impact of Microsatellite Instability and DNA Ploidy in Human Colon Carcinoma Patients. Gastroenterology, 2006, 131, 729-737.	0.6	195
281	Randomized Clinical Trial of High-Dose Levamisole Combined with 5-Fluorouracil and Leucovorin as Surgical Adjuvant Therapy for High-Risk Colon Cancer. Clinical Colorectal Cancer, 2006, 6, 133-139.	1.0	28
282	Current Issues in Adjuvant Treatment of Stage II Colon Cancer. Annals of Surgical Oncology, 2006, 13, 887-898.	0.7	89
283	Microsatellite Instability Accounts for Tumor Site-Related Differences in Clinicopathologic Variables and Prognosis in Human Colon Cancers. American Journal of Gastroenterology, 2006, 101, 2818-2825.	0.2	70
284	Pick the Winner Designs in Phase II Cancer Clinical Trials. Journal of Thoracic Oncology, 2006, 1, 5-6.	0.5	8
285	Pick the Winner Designs in Phase II Cancer Clinical Trials. Journal of Thoracic Oncology, 2006, 1, 5-6.	0.5	4
286	An adaptive dose-finding design incorporating both toxicity and efficacy. Statistics in Medicine, 2006, 25, 2365-2383.	0.8	159
287	Is En-Bloc Resection of Locally Recurrent Rectal Carcinoma Involving the Urinary Tract Indicated?. Annals of Surgical Oncology, 2006, 13, 740-744.	0.7	14
288	Thymidylate Synthase Expression in Colon Carcinomas with Microsatellite Instability. Clinical Cancer Research, 2006, 12, 2738-2744.	3.2	42

#	ARTICLE	IF	CITATIONS
289	Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 4085-4091.	0.8	443
290	End Points for Adjuvant Therapy Trials: Has the Time Come to Accept Disease-Free Survival as a Surrogate End Point for Overall Survival?. <i>Oncologist</i> , 2006, 11, 624-629.	1.9	66
291	Sam Wieand, PhD. <i>Journal of Clinical Oncology</i> , 2006, 24, 4523-4525.	0.8	9
292	Duffy-Santner Confidence Intervals for the Two-Stage Three-Outcome Design. <i>Journal of Biopharmaceutical Statistics</i> , 2006, 16, 875-880.	0.4	1
293	General and statistical hierarchy of appropriate biologic endpoints. <i>Oncology</i> , 2006, 20, 5-9.	0.4	62
294	Pick the winner designs in phase II cancer clinical trials. <i>Journal of Thoracic Oncology</i> , 2006, 1, 5-6.	0.5	3
295	A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. <i>Surgery</i> , 2005, 138, 618-630.	1.0	462
296	A pilot study of high-dose intraarterial cisplatin chemotherapy with concomitant accelerated radiotherapy for patients with previously untreated T4 and selected patients with T3N0-N3M0 squamous cell carcinoma of the upper aerodigestive tract. <i>Cancer</i> , 2005, 103, 559-568.	2.0	31
297	Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. <i>Cancer</i> , 2005, 104, 1871-1884.	2.0	33
298	Isolated Loss of PMS2 Expression in Colorectal Cancers: Frequency, Patient Age, and Familial Aggregation. <i>Clinical Cancer Research</i> , 2005, 11, 6466-6471.	3.2	54
299	Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1402-1410.	1.1	18
300	Adjuvant Therapy for Colon Cancer "The Pace Quickens. <i>New England Journal of Medicine</i> , 2005, 352, 2746-2748.	13.9	22
301	Oxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 9243-9249.	0.8	475
302	Overall Survival of Patients With Advanced Colorectal Cancer Correlates With Availability of Fluorouracil, Irinotecan, and Oxaliplatin Regardless of Whether Doublet or Single-Agent Therapy Is Used First Line. <i>Journal of Clinical Oncology</i> , 2005, 23, 9441-9442.	0.8	226
303	Dealing With a Deluge of Data: An Assessment of Adverse Event Data on North Central Cancer Treatment Group Trials. <i>Journal of Clinical Oncology</i> , 2005, 23, 9275-9281.	0.8	37
304	FOLFOX for Stage II Colon Cancer? A Commentary on the Recent FDA Approval of Oxaliplatin for Adjuvant Therapy of Stage III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 3311-3313.	0.8	23
305	Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials. <i>Journal of Clinical Oncology</i> , 2005, 23, 8664-8670.	0.8	607
306	Clinical Trial Designs for Prospective Validation of Biomarkers. <i>Molecular Diagnosis and Therapy</i> , 2005, 5, 317-325.	3.3	44

#	ARTICLE	IF	CITATIONS
307	Clinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials. <i>Journal of Clinical Oncology</i> , 2005, 23, 2020-2027.	0.8	473
308	5-Fluorouracil-Based Chemotherapy for Advanced Colorectal Cancer in Elderly Patients: A North Central Cancer Treatment Group Study. <i>Clinical Colorectal Cancer</i> , 2005, 4, 325-331.	1.0	39
309	A Comparison of Laparoscopically Assisted and Open Colectomy for Colon Cancer. <i>New England Journal of Medicine</i> , 2004, 350, 2050-2059.	13.9	3,258
310	New Treatment Options for Colorectal Cancer. <i>New England Journal of Medicine</i> , 2004, 351, 391-392.	13.9	35
311	Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?. <i>Journal of Clinical Oncology</i> , 2004, 22, 1797-1806.	0.8	913
312	Phase III Study of Adjuvant Chemotherapy and Radiation Therapy Compared With Chemotherapy Alone in the Surgical Adjuvant Treatment of Colon Cancer: Results of Intergroup Protocol 0130. <i>Journal of Clinical Oncology</i> , 2004, 22, 3277-3283.	0.8	109
313	Substitution of Oral Fluoropyrimidines for Infusional Fluorouracil With Radiotherapy: How Much Data Do We Need?. <i>Journal of Clinical Oncology</i> , 2004, 22, 2978-2981.	0.8	27
314	Prognostic Value of Proliferation, Apoptosis, Defective DNA Mismatch Repair, and p53 Overexpression in Patients With Resected Dukes' B2 or C Colon Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 1572-1582.	0.8	119
315	Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment. <i>Journal of Clinical Oncology</i> , 2004, 22, 1209-1214.	0.8	1,007
316	Impact of T and N Stage and Treatment on Survival and Relapse in Adjuvant Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 1785-1796.	0.8	419
317	Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin. <i>Cancer</i> , 2004, 101, 2170-2176.	2.0	66
318	A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 23-30.	0.8	2,112
319	Intraoperative radiotherapy for head and neck and skull base cancer. <i>Head and Neck</i> , 2003, 25, 217-226.	0.9	28
320	A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 1305-1310.	0.4	30
321	Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer. <i>New England Journal of Medicine</i> , 2003, 349, 247-257.	13.9	1,962
322	Molecular Diagnostics: Assays, Tissues, Progress, and Pitfalls. <i>Journal of Clinical Oncology</i> , 2003, 21, 395-396.	0.8	13
323	Title is missing!. <i>Annals of Surgery</i> , 2003, 237, 502-508.	2.1	36
324	Efficacy and Quality-of-Life Data Are Related in a Phase II Trial of Oral Chemotherapy in Previously Untreated Patients With Metastatic Colorectal Carcinoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 4574-4580.	0.8	40

#	ARTICLE	IF	CITATIONS
325	Early Detection of Toxicity and Adjustment of Ongoing Clinical Trials: The History and Performance of the North Central Cancer Treatment Group's Real-Time Toxicity Monitoring Program. <i>Journal of Clinical Oncology</i> , 2002, 20, 4591-4596.	0.8	37
326	Immunohistochemistry Versus Microsatellite Instability Testing in Phenotyping Colorectal Tumors. <i>Journal of Clinical Oncology</i> , 2002, 20, 1043-1048.	0.8	511
327	Investigation of the Prognostic and Predictive Value of Thymidylate Synthase, p53, and Ki-67 in Patients With Locally Advanced Colon Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 1735-1743.	0.8	158
328	Short-term Quality-of-Life Outcomes Following Laparoscopic-Assisted Colectomy vs Open Colectomy for Colon Cancer<SUBTITLE>A Randomized Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 321.	3.8	675
329	Women Experience Greater Toxicity With Fluorouracil-Based Chemotherapy for Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 1491-1498.	0.8	192
330	Issues in clinical trial design for tumor marker studies. <i>Seminars in Oncology</i> , 2002, 29, 222-230.	0.8	58
331	Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 469-475.	0.4	171
332	Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 409-413.	0.4	25
333	Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 386-396.	0.4	148
334	A new graphic for quality adjusted life years (Q-TWiST) survival analysis: the Q-TWiST plot. <i>Quality of Life Research</i> , 2002, 11, 37-45.	1.5	9
335	Guidelines 2000 for Colon and Rectal Cancer Surgery. <i>Journal of the National Cancer Institute</i> , 2001, 93, 583-596.	3.0	1,174
336	Impact of Surgical and Pathologic Variables in Rectal Cancer: A United States Community and Cooperative Group Report. <i>Journal of Clinical Oncology</i> , 2001, 19, 3895-3902.	0.8	199
337	A flexible design for multiple armed screening trials. <i>Statistics in Medicine</i> , 2001, 20, 1051-1060.	0.8	81
338	Comparison of artificial neural networks with other statistical approaches. <i>Cancer</i> , 2001, 91, 1636-1642.	2.0	256
339	A Three-Outcome Design for Phase II Clinical Trials. <i>Contemporary Clinical Trials</i> , 2001, 22, 117-125.	2.0	74
340	Counting degrees of freedom in hierarchical and other richly-parameterised models. <i>Biometrika</i> , 2001, 88, 367-379.	1.3	110
341	A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients. <i>New England Journal of Medicine</i> , 2001, 345, 1091-1097.	13.9	931
342	Refining Multimodal Therapy for Rectal Cancer. <i>New England Journal of Medicine</i> , 2001, 345, 690-692.	13.9	68

#	ARTICLE	IF	CITATIONS
343	Enhanced Therapeutic Potential of Adoptive Immunotherapy by In Vitro CD28/4-1BB Costimulation of Tumor-Reactive T Cells Against a Poorly Immunogenic, Major Histocompatibility Complex Class I-Negative A9P Melanoma. <i>Journal of Immunotherapy</i> , 2000, 23, 430-437.	1.2	36
344	A north central cancer treatment group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma. <i>Cancer</i> , 2000, 89, 1699-1705.	2.0	15
345	PHASE II STUDY OF PACLITAXEL AND CISPLATIN FOR ADVANCED UROTHELIAL CANCER. <i>Journal of Urology</i> , 2000, 164, 1538-1542.	0.2	64
346	Prognostic Factors in Colorectal Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2000, 124, 979-994.	1.2	1,027
347	Statistical Issues in Tumor Marker Studies. <i>Archives of Pathology and Laboratory Medicine</i> , 2000, 124, 1011-1015.	1.2	37
348	Decrease in cranial nerve complications after radiosurgery for acoustic neuromas: a prospective study of dose and volume. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 43, 305-311.	0.4	112
349	Sample Size and Design Considerations for Phase II Clinical Trials with Correlated Observations. <i>Contemporary Clinical Trials</i> , 1999, 20, 242-252.	2.0	9
350	The radial distance of extraprostatic extension of prostate carcinoma. , 1999, 85, 2630-2637.		134
351	The radial distance of extraprostatic extension of prostate carcinoma. , 1999, 85, 2630.		34
352	Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998, 41, 593-598.	0.4	62
353	A General Framework for Random Effects Survival Analysis in the Cox Proportional Hazards Setting. <i>Biometrics</i> , 1998, 54, 1486.	0.8	95
354	A flexible approach to time-varying coefficients in the Cox regression setting. , 1997, 3, 13-25.		38
355	ROBUST BAYESIAN APPROACHES FOR CLINICAL TRIAL MONITORING. , 1996, 15, 1093-1106.		29
356	Gastrointestinal Cancers. , 0, , 81-104.		0